Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
3.
Medicine (Madr) ; 11(53): 3165-3170, 2014 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-32287898

RESUMO

Imported parasitoses are an uncommon condition in our setting, although recently, the increase of migratory flow has been leading to an increase in the detected cases of these diseases. This fundamentally occurs in immigrants from tropical zones where these conditions are generally endemic. However, imported parasitoses are being increasingly diagnosed in Western persons who have lived in the tropics for different reasons. When examining a subject with cardiovascular syndromes with a possible parasitic origin, it could be useful to classify the possible geographic zone of origin in order to perform disease screening. Then, if the problem is mainly respiratory, it would be well to first rule out the existence of tuberculosis in the case of long stays and to individual the diagnosis according to the geographic area, season of the year, type of exposure and symptoms presented, in the case of shorter stays.

4.
Rev Esp Anestesiol Reanim ; 61(2): 109-11, 2014 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-23276378

RESUMO

Hepatotoxicity is a rare complication following the use of propofol and can be potentially serious if an early diagnosis is not made. Propofol is being increasingly used in daily practice, not only in surgery, but also in outpatient sedation procedures, such as endoscopy. Acarbose is a well-known drug used in type 2 diabetes treatment, particularly in the early phase. A case is reported on a patient who suffered an acute hepatitis secondary to the use of propofol in ophthalmology surgery, a hepatitis probably enhanced by prior use of acarbose, a drug that also can cause hepatotoxicity. An early diagnosis and it was resolved without complications. This case could contribute to improve pre-anesthetic evaluation of patients who will be undergoing sedation with propofol in order to avoid the possible appearance of hepatitis.


Assuntos
Acarbose/efeitos adversos , Anestésicos Intravenosos/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Hipoglicemiantes/efeitos adversos , Propofol/efeitos adversos , Acarbose/farmacocinética , Acarbose/uso terapêutico , Idoso , Anestesia Intravenosa , Anestésicos Intravenosos/farmacocinética , Diabetes Mellitus Tipo 2/tratamento farmacológico , Interações Medicamentosas , Feminino , Humanos , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/uso terapêutico , Implante de Lente Intraocular , Facoemulsificação , Propofol/farmacocinética , Fatores de Tempo
7.
Rev Clin Esp ; 207(2): 64-8, 2007 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-17397564

RESUMO

OBJECTIVE: The primary objective of this study was to determine the prevalence of Metabolic Syndrome (MS) in people between 40-70 years of age in the province of Albacete (Spain). PATIENTS AND METHODS: A population-based, cross-sectional study was made of people between 40-70 years of age in three representative municipalities of the province of Albacete. A total of 425 subjects were included, with a mean age of 53.1 years (95% CI: 52.3-54). Women represented 50.4% of the series and males 49.6%. All participants were subjected to general laboratory testing, physical examination and the measurement of anthropometric parameters. MS was defined according to the ATP-III criteria. Prevalence of MS and its distribution according to the different epidemiological characteristics were calculated. RESULTS: Total prevalence of MS was 20.9% (88/421), with a mean age of 57 years (95% CI: 55.1-59). Prevalence was seen to increase with age, reaching up to one-third of all subjects over 60 years. Significant differences were observed in relationship to a background of ischemic heart disease, ultrasensitive C-reactive protein elevation and the detection of microalbuninuria in MS subjects. Arterial hypertension and abdominal obesity were the most prevalent criteria in MS subjects. CONCLUSIONS: Taking into consideration the important co-morbidity of MS, knowledge of the prevalence and characteristics of the syndrome in our setting and its early identification and intervention targeted to the different factors underlying MS will contribute to reduce the number of cardiovascular events associated with the syndrome.


Assuntos
Síndrome Metabólica/epidemiologia , Adulto , Fatores Etários , Idoso , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Estudos Transversais , Feminino , Humanos , Masculino , Síndrome Metabólica/complicações , Síndrome Metabólica/diagnóstico , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Fatores Sexuais , Espanha/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA